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Summary
 Background The biological effectiveness of elevated temperature (hyperthermia) on cancer 
cells is a well documented issue. Nevertheless, it is still not widely used in clini-
cal practice, mainly due to technical difﬁ culties. The main limiting factor is the 
protection of healthy tissue during the hyperthermia procedure. Hyperthermia, 
used as an adjuvant treatment with brachytherapy, provides the possibility of low-
ering total radiation doses, without reducing biological effects.
 Aim The aim of this work was to present the advantages of using 500 kHz hyperther-
mia in HDR brachytherapy of cervical & endometrial cancer.
 Materials/Methods Hyperthermia procedures were performed in 8 endometrial cancer patients and 
2 cervical cancer patients with early recurrent local disease in previously irradiat-
ed areas. One or two interstitial hyperthermia procedures were performed using 
rigid metal needles, both for brachytherapy and temperature elevation. The to-
tal radiation dose was 30 Gy, delivered in 3 or 6 Gy per fraction. In the case of 3 
Gy per fraction, a scheme of two fractions per day, separated by at least 8 hours, 
was used. The total treatment time ranged from 5 to 14 days. Hyperthermia was 
performed concurrently with brachytherapy.
 Results During the treatment, no acute reactions were observed. In each case, tumour 
regression over 50% was noted. During the 3 to 14 month follow-up period, com-
plete vaginal tumour regression was seen in 8 of 10 cases.
 Conclusions 500 kHz hyperthermia assisted interstitial brachytherapy can be regarded as effec-
tive and safe procedure, especially when applied as secondary (salvage) treatment. 
More cases and longer observation time are needed to make deﬁ nite conclusions.
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BACKGROUND
Despite diagnostic and therapeutic progress, cer-
vical cancer still has one of the worst epidemio-
logical indices in Poland. Data analysis for the 
year 2000, has shown a morbidity level of 6.8% 
and a mortality level 5.4% for all malignancies. 
During the same period, 3597 new cases of cervi-
cal cancer were diagnosed and 1987 deaths were 
recorded as being caused by this disease [1]. In 
quite a large proportion of patients, because of 
the advanced clinical stage of the disease (IIB-
IIIB according to FIGO), the treatment of choice 
is radiotherapy or radio-chemotherapy with in-
tent to-treat. To reach the optimum dose distri-
bution, the accepted standard is to supplement 
the dose delivered during external beam radio-
therapy, with intracavitary brachytherapy [2]. The 
epidemiological indices for endometrial cancer, 
during the same year were 3276 (6.2% of all ma-
lignancies), and are not so pessimistic. During 
the year 2000, a total of 808 deaths caused by en-
dometrial cancer were noted, which accounts for 
2.2% of all deaths caused by these malignancies. 
Better results of therapy in this case are mainly ow-
ing to less advanced disease which gives the pos-
sibility for radical surgical treatment (and even-
tual adjuvant external beam or brachytherapy) 
[3]. In either of the above mentioned tumour 
sites, there may be some problems with patients 
suffering from relapse in a previously irradiat-
ed ﬁ eld. Co-exisitng conditions and the impos-
sibility of injury avoidance, often exclude surgi-
cal treatment, while the tolerance dose of critical 
organs makes secondary irradiation impossible. 
Improved biological effectiveness from elevated 
temperatures (hyperthermia) on cancer cells and 
the potential of its association with radiotherapy 
is a well known issue. Nevertheless it is not used 
widely enough in oncological practice. The main 
limiting factors are technical difﬁ culties regard-
ing hyperthermia procedures. The problems are 
connected with limited capabilities in obtaining 
therapeutic temperatures (>42.5°C) inside the 
tumour while maintaining healthy tissue protec-
tion. Hyperthermia, used as a complementary 
treatment to radiotherapy provides the possibili-
ty to deliver lower doses with the same biological 
effects. Interstitial brachytherapy may enhance 
this phenomenon by reducing the irradiated vol-
ume and makes it possible to deliver simultane-
ous hyperthermia to the irradiated tissues via the 
same applicators. A unique therapeutic HT-2 set, 
used in the Centre of Oncology, allows the prac-
tical use of hyperthermia in the treatment of cer-
vical and endometrial cancer [4].
MATERIALS
Hyperthermia procedures were performed in 
10 patients: 8 endometrial cancer cases and 2 
cervical cancer patients with early recurrence in 
a previously irradiated ﬁ eld. Hyperthermia was 
combined with interstitial HDR brachytherapy. 
Patients were aged between 46 and 75 years (av-
erage 65). All the patients underwent, prior to re-
currence detection, primary post-operative, exter-
nal beam irradiation (box technique, 46Gy/23fr) 
with the addition of vaginal cuff HDR brachy-
therapy (2–3 × 7,5Gy/fr/0,5cm from the appli-
cator surface).
METHODS
An HT-2 set with a 500 kHz frequency generator 
[4] was used. One or two interstitial hyperther-
mia procedures were performed, using rigid met-
al needles for an HDR Ir-192 source (Gammamed 
12i) and for energy transmission. The total dose 
was 30 Gy, dose per fraction 3 or 6 Gy, and to-
tal treatment time was from 5 to 14 days. In the 
case of 3 Gy per fraction, irradiation was per-
formed twice daily with an interval of at least 8 
hours. Dose distribution calculations were based 
on x-ray needle localizations using the Abacus 
computer planning system. The dose was speci-
ﬁ ed as 0.5–0.7 mm from the needle surface. The 
irradiated volume ranged from 25 to 50 cm3 (av-
erage 30 cm3). For this group of patients, thanks 
to the mobility and the compact size of the HT-2 
set, unique application of brachytherapy during 
the hyperthermia procedure was possible (after 
the therapeutic values of the temperatures were 
obtained, brachytherapy was started, without in-
terruption of the hyperthermia procedure). In 
each case, in order to avoid the thermoresist-
ance effect, the hyperthermia procedure was per-
formed at 48 hours intervals. The total treatment 
time was 45–60 minutes and included at least 45 
minutes with temperatures at up to 46–49°C.
RESULTS
Early sequelae, which may have caused interrup-
tions in treatment, were not observed. In every 
case, irradiation reactions appeared as erythema 
with superﬁ cial subsidence of the epithelium and 
intensiﬁ ed mucous secretion. Rectal and bladder 
reactions were observed in 6 patients but were lim-
ited to grade I, according to the EORTC/RTOG 
scale, and were cured spontaneously. Follow-ups 
were performed one month after treatment and 
every 3 months thereafter. Post-irradiation reaction 
Original Paper Rep Pract Oncol Radiother, 2005; 10(3): 131-134
132
symptoms disappeared 2–3 months after conserva-
tive treatment (local steroids, vessel wall protectant 
/ oxerutin / anti-infamatory agents / diclofenac). 
No late side-effects were observed. During the fol-
low-up period of 3 to 14 months, complete vagi-
nal tumour regression was conﬁ rmed by clinical 
examination in 8/10 cases. In two cases no regres-
sion was seen. In one case of cervical cancer, a tu-
mour of 4 cm was observed in CT scans before 
treatment. Complete regression of the tumour 
was seen after treatment. This effect lasted for 10 
months. This patient died as a result of sigmoid 
perforation, followed by peritonitis. From the sur-
gical point of view, the observed lesions were lo-
cated outside the re-irradiated volume. The per-
foration was owing to sigmoid occlusion caused by 
adhesions. In a second case, after 5 months follow-
up with complete regression, vaginal recurrence 
(outside the re-irradiated ﬁ eld) and pulmonary 
metastases were detected. In this case, chemo-
therapy according to the PAC scheme (cis-platin, 
adriamycine, cyclophosphamide) was performed. 
Tumour stabilization was observed.
DISCUSSION
The treatment of early recurrence in previously 
irradiated ﬁ elds is not an easy task. The possibil-
ities for surgical treatment are often limited be-
cause of the impossibility of obtaining optimal 
margins without serious injury to the patient (of-
ten colpectomy or ureterotomy). Further irradia-
tion is often impossible owing to risks in exceed-
ing the tolerance doses for healthy tissues. The 
only alternative method is chemotherapy, which 
cannot be regarded as radical treatment. It seems 
that the most interesting possibility for this group 
of patients is the application of hyperthermia as 
a method for strengthening the effects of radia-
tion therapy [5]. Several recently published pa-
pers show a higher index of clinical effectivness 
after incorporating hyperthermia into radiother-
apy. Among the most relevant of these are the re-
sults of the “Dutch Deep Hyperthermia Group”. 
This was a prospective, randomised, multi-centre 
study based on the treatment results of 358 pa-
tients with cervical, rectal or bladder cancers. In 
this group, the 114 patients with cervical cancer 
were divided into two subgroups – 58 patients 
received radiotherapy and hyperthermia and 56 
patients received radiotherapy alone. Local con-
trol rates were 61% and 41% with 3-year survival 
times being 51% and 27% respectively and be-
ing statistically signiﬁ cant. In the subgroup of pa-
tients with rectal cancer (143 patients) no statis-
tically relevant difference was observed. Again, 
the local control rates were respectively 16% and 
8% with 3-year survival times of 22% and 13% re-
spectively. For the 101 patients with bladder can-
cer respective values were 42% versus 33% and 
28% versus 22%[6]. It is very important to note 
that these results were obtained using “external 
heating” which is not so effective as intracavitary 
heating due to treatment intolerance and a low-
er range of temperatures.
In a randomised trial by Harima et al, assessing 
the concentration of Bax and Bcl-2 proteins in 
irradiated cervical carcinoma cells, signiﬁ cant-
ly different protein concentrations were found 
when treatment by hyperthermia and radiother-
apy was compared with radiotherapy alone. This 
was positively correlated with the percentage of 
complete tumour regression (83.3% in the hyper-
thermia combined group vs. 52.6% in the radio-
therapy alone group). A negative correlation was 
observed with lack of response (5.6% vs. 21.1% 
respectively) [7].
Vasanthan et al. found no beneﬁ ts from the addi-
tion of hyperthermia to radiotherapy in cervical 
cancer patients. It should be pointed out that the 
temperatures achieved in this study were in many 
cases signiﬁ cantly lower than needed minimum 
of 42.5°C [8]. Being multi-centered, this study 
included a very limited number of patients from 
each institution (1–27) and irradiation was per-
formed in a non-uniform manner. The hyperther-
mia procedure was performed using different ma-
chines and using different protocols. Temperature 
measurements were not performed in more than 
50% of the hyperthermia sessions. With respect 
to the increasing efﬁ ciency of radiotherapy, lim-
itation of the total dose and avoidance of late se-
quelae are possible. An interesting observation 
was made by Van der Zee et al. [9] while evalu-
ating post-irradiation injuries in post mastecto-
my breast cancer patients, treated for scar recur-
rence. Two adjacent regions of the thoracic wall 
were irradiated with the same dose. The differ-
ence between these areas was the addition of si-
multaneous hyperthermia to irradiation therapy 
in one ﬁ eld. As a result, signiﬁ cantly fewer signs 
of telangiectasia were observed in hyperthermia 
treated ﬁ elds. Authors associate this with faster 
sub-lethal injury repairs to intraepithelial cells 
damaged during irradiation. In their study, Li et 
al. [10], treating breast cancer patients with recur-
rence, conﬁ rmed a higher percentage of complete 
remissions in previously irradiated ﬁ elds when 
hyperthermia was added. Even signiﬁ cantly low-
er doses (43 Gy in radiotherapy + hyperthermia 
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group vs. 59.5 Gy in radiotherapy alone group), 
were more effective when hyperthermia was ap-
plied. In a recently published paper, Kouloulias 
et al. showed a higher sphincter preservation rate 
(95.8% radiotherapy + hyperthermia vs. 68.0% 
radiotherapy alone) when hyperthermia was add-
ed to the standard radio-chemotherapy of anal 
cancer patients [11].
With respect to the necessarily high radiation dos-
es used in gynaecological malignancies, hyper-
thermia provides a means to limit radiation in-
duced injuries. This fact is crucial in the case of 
re-irradiation. Studies with practical hyperther-
mia application, performed over several years 
at Centre of Oncology in Warsaw [4,12], con-
ﬁ rmed its biological effect and proves its prac-
tical usefulness. In particular, simultaneous in-
terstitial brachytherapy and hyperthermia allows 
us to take maximum advantage of the combina-
tion of both methods [13,14]. To date, howev-
er, the results presented above refer to a small 
group of patients with relatively short follow-up. 
Nevertheless, on this basis we may take advan-
tage of the therapeutic potential of simultane-
ous hyperthermia and radiotherapy.
CONCLUSIONS
A 500 kHz hyperthermia assisted interstitial brachy-
therapy can be regarded as effective and safe proce-
dure, specially when applied as secondary (salvage) 
treatment. More cases and longer observation time 
are needed to make deﬁ nite conclusions.
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